Bio-Techne (TECH) Stock Price, News & Analysis

Company Overview

Bio-Techne Corporation (NASDAQ:TECH) is a global provider of life science reagents, instruments and services that support research, diagnostics and bioprocessing applications. The company’s offerings include cytokines, growth factors, immunoassays, antibodies, enzymes, proteins and nucleic acid reagents designed to enable scientists to quantify, characterize and manipulate biological systems. Bio-Techne’s portfolio also incorporates advanced instrumentation platforms for protein analysis, cell analysis, digital PCR and spatial biology.

Through its core brands—such as R&D Systems, Novus Biologicals, Tocris, ProteinSimple and Advanced Cell Diagnostics—Bio-Techne serves a diverse customer base spanning academic and government research institutions, biotechnology and pharmaceutical companies, clinical laboratories and biomanufacturers. The company’s products are used in basic research, drug discovery, biomarker identification, therapeutic development, personalized medicine and quality control in biologics manufacturing.

Since its founding in 1976, Bio-Techne has expanded both organically and through strategic acquisitions to broaden its technological capabilities and geographic reach. Key acquisitions have included ProteinSimple in 2014, which added microfluidic and capillary electrophoresis platforms, and Advanced Cell Diagnostics in 2019, which bolstered the company’s spatial biology and in situ hybridization offerings. Headquartered in Minneapolis, Minnesota, Bio-Techne maintains research, manufacturing and distribution sites across North America, Europe and Asia.

Under the leadership of President and Chief Executive Officer Charles Kummeth, Bio-Techne emphasizes innovation, customer support and strategic investment in emerging life science technologies. The company’s senior management team and board of directors draw on extensive industry experience to guide growth initiatives, foster partnerships with academic and commercial organizations, and invest in next-generation tools for proteomics, genomics and cell analysis.

Key Stats

• Today's Range: $51.83 to $53.61
• 50-Day Range: $46.66 to $53.90
• 52-Week Range: $46.01 to $83.62
• Volume: 843,577 shs
• Average Volume: 1.46 million shs
• Market Capitalization: $8.25 billion
• P/E Ratio: 64.25
• Dividend Yield: 0.61%
• Price Target: $71.36
• Consensus Rating: Moderate Buy

Bio-Techne Stock Analysis - MarketRank™

Bio-Techne scored higher than 99% of companies evaluated by MarketBeat, and ranked 16th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Bio-Techne has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, 6 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Bio-Techne has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 17.96%

Earnings Growth

Earnings for Bio-Techne are expected to grow by 17.96% in the coming year, from $1.67 to $1.97 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bio-Techne is 63.49, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.92.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bio-Techne is 63.49, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.18.

Price to Earnings Growth Ratio

Bio-Techne has a PEG Ratio of 2.45. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Bio-Techne has a P/B Ratio of 3.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.08% of the float of Bio-Techne has been sold short.

Short Interest Ratio / Days to Cover

Bio-Techne has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bio-Techne has recently decreased by 18.57%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Bio-Techne has a dividend yield of 0.60%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Bio-Techne does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Bio-Techne is 39.02%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Bio-Techne will have a dividend payout ratio of 16.24% next year. This indicates that Bio-Techne will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.64

Percentage of Shares Shorted

4.08% of the float of Bio-Techne has been sold short.

Short Interest Ratio / Days to Cover

Bio-Techne has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bio-Techne has recently decreased by 18.57%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 1.27

News Sentiment

Bio-Techne has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Bio-Techne this week, compared to 11 articles on an average week.

Search Interest

Only 4 people have searched for TECH on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Bio-Techne to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bio-Techne insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.90% of the stock of Bio-Techne is held by insiders.

Percentage Held by Institutions

98.95% of the stock of Bio-Techne is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TECH Stock Analysis - Frequently Asked Questions

How have TECH shares performed this year?

Bio-Techne's stock was trading at $72.03 at the start of the year. Since then, TECH shares have decreased by 27.6% and is now trading at $52.18.

How were Bio-Techne's earnings last quarter?

Bio-Techne Corp (NASDAQ:TECH) announced its quarterly earnings data on Wednesday, May, 7th. The biotechnology company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.51 by $0.05. Bio-Techne's revenue for the quarter was up 4.2% on a year-over-year basis.
Read the conference call transcript.

When did Bio-Techne's stock split?

Bio-Techne's stock split on the morning of Wednesday, November 30th 2022.The 4-1 split was announced on Tuesday, November 1st 2022. The newly issued shares were distributed to shareholders after the closing bell on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

Is Bio-Techne buying back stock?

Bio-Techne's board initiated a stock buyback program on Wednesday, May 7th 2025, which authorizes the company to buy back $500,000,000 in outstanding shares, according to EventVestor. This means that the company could repurchase up to 6.5% of its shares through open market purchases. Shares buyback programs are generally an indication that the company's leadership believes its stock is undervalued.

Does Bio-Techne have any subsidiaries?

Bio-Techne subsidiaries include these companies: MoGen Biotechnologies, Exosome Diagnostics, Quad Technologies, Advanced Cell Diagnostics, Space Import-Export Srl, Zephyrus Biosciences, Cliniqa, and more.

Who are Bio-Techne's major shareholders?

Bio-Techne's top institutional investors include Rowlandmiller & PARTNERS.ADV (0.03%), Czech National Bank (0.02%), Kera Capital Partners Inc. and Central Pacific Bank Trust Division. Insiders that own company stock include Roeland Nusse, Kim Kelderman, Brenda S Furlow, John L Higgins and Amy E Herr.
View institutional ownership trends.

How do I buy shares of Bio-Techne?

Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bio-Techne own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bio-Techne investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Netflix (NFLX).

Company Calendar

• Last Earnings: 5/07/2025
• Record date for 5/30 Dividend: 5/19/2025
• Ex-Dividend for 5/30 Dividend: 5/19/2025
• Dividend Payable: 5/30/2025
• Today: 7/09/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:TECH
• CIK: 842023
• Web: www.bio-techne.com
• Phone: (612) 379-8854
• Fax: 612-656-4400
• Employees: 3,100
• Year Founded: 1981

Price Target and Rating

• Average Price Target for Bio-Techne: $71.36
• High Price Target: $90.00
• Low Price Target: $59.00
• Potential Upside/Downside: +34.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.82
• Trailing P/E Ratio: 64.95
• Forward P/E Ratio: 31.84
• P/E Growth: 2.45
• Net Income: $168.10 million
• Net Margins: 10.89%
• Pretax Margin: 13.48%
• Return on Equity: 13.17%
• Return on Assets: 10.17%

Debt

• Debt-to-Equity Ratio: 0.16
• Current Ratio: 3.71
• Quick Ratio: 2.58

Sales & Book Value

• Annual Sales: $1.21 billion
• Price / Sales: 6.90
• Cash Flow: $2.39 per share
• Price / Cash Flow: 22.27
• Book Value: $13.13 per share
• Price / Book: 4.05

Miscellaneous

• Outstanding Shares: 156,767,000
• Free Float: 150,653,000
• Market Cap: $8.34 billion
• Optionable: Optionable
• Beta: 1.39